|
1
|
Romero I and Bast RC Jr: Minireview: Human
ovarian cancer: Biology, current management, and paths to
personalizing therapy. Endocrinology. 153:1593–1602. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cancer Genome Atlas Research Network, .
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
BastRC Jr, Hennessy B and Mills GB: The
biology of ovarian cancer: New opportunities for translation. Nat
Rev Cancer. 9:415–428. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pal T, PermuthWey J, Betts JA, Krischer
JP, Fiorica J, Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley
K, et al: BRCA1 and BRCA2 mutations account for a large proportion
of ovarian carcinoma cases. Cancer. 104:2807–2816. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Etemadmoghadam D, AuYeung G, Wall M,
Mitchell C, Kansara M, Loehrer E, Batzios C, George J, Ftouni S,
Weir BA, et al: Resistance to CDK2 inhibitors is associated with
selection of polyploid cells in CCNE1-amplified ovarian cancer.
Clin Cancer Res. 19:5960–5971. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dawson MA, Prinjha RK, Dittmann A,
Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C,
Savitski MM, et al: Inhibition of BET recruitment to chromatin as
an effective treatment for MLL-fusion leukaemia. Nature.
478:529–533. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Delmore JE, Issa GC, Lemieux ME, Rahl PB,
Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et
al: BET bromodomain inhibition as a therapeutic strategy to target
c-Myc. Cell. 146:904–917. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mertz JA, Conery AR, Bryant BM, Sandy P,
Balasubramanian S, Mele DA, Bergeron L and Sims RJ III: Targeting
MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl
Acad Sci USA. 108:16669–16674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zuber J, Shi J, Wang E, Rappaport AR,
Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, et al:
RNAi screen identifies Brd4 as a therapeutic target in acute
myeloid leukaemia. Nature. 478:524–528. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lovén J, Hoke HA, Lin CY, Lau A, Orlando
DA, Vakoc CR, Bradner JE, Lee TI and Young RA: Selective inhibition
of tumor oncogenes by disruption of super-enhancers. Cell.
153:320–334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:p112013. View Article : Google Scholar
|
|
13
|
Fu LL, Tian M, Li X, Li JJ, Huang J,
Ouyang L, Zhang Y and Liu B: Inhibition of BET bromodomains as a
therapeutic strategy for cancer drug discovery. Oncotarget.
6:5501–5516. 2015.PubMed/NCBI
|
|
14
|
Puissant A, Frumm SM, Alexe G, Bassil CF,
Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P,
et al: Targeting MYCN in neuroblastoma by BET bromodomain
inhibition. Cancer Discov. 3:308–323. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi J and Vakoc CR: The mechanisms behind
the therapeutic activity of BET bromodomain inhibition. Mol Cell.
54:728–736. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Goundiam O, Gestraud P, Popova T, De la
Motte Rouge T, Fourchotte V, Gentien D, Hupé P, Becette V, Houdayer
C, RomanRoman S, et al: Histo-genomic stratification reveals the
frequent amplification/overexpression of CCNE1 and BRD4 genes in
non-BRCAness high grade ovarian carcinoma. Int J Cancer Apr.
17:2015.(Epub ahead of print).
|
|
17
|
Baratta MG, Schinzel AC, Zwang Y,
Bandopadhayay P, BowmanColin C, Kutt J, Curtis J, Piao H, Wong LC,
Kung AL, et al: An in-tumor genetic screen reveals that the BET
bromodomain protein, BRD4, is a potential therapeutic target in
ovarian carcinoma. Proc Natl Acad Sci USA. 112:232–237. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shi J, Whyte WA, ZepedaMendoza CJ, Milazzo
JP, Shen C, Roe JS, Minder JL, Mercan F, Wang E, EckersleyMaslin
MA, et al: Role of SWI/SNF in acute leukemia maintenance and
enhancer-mediated Myc regulation. Genes Dev. 27:2648–2662. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
YashiroOhtani Y, Wang H, Zang C, Arnett
KL, Bailis W, Ho Y, Knoechel B, Lanauze C, Louis L, Forsyth KS, et
al: Long-range enhancer activity determines Myc sensitivity to
Notch inhibitors in T cell leukemia. Proc Natl Acad Sci USA.
111:E4946–E4953. 2014. View Article : Google Scholar : PubMed/NCBI
|
